Transthera Sciences (Nanjing), Inc.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-04-15
- Employees
- 51
- Market Cap
- -
- Website
- http://www.transtherabio.com
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsCholangiocarcinoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Registration Number
- NCT06370013
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
- Conditions
- Cholangiocarcinoma Metastatic
- Interventions
- Drug: TT-00420 (tinengotinib)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06057571
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05948475
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸The University of Kansas Cancer Center, Westwood, California, United States
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
- Conditions
- B-Cell Malignancies
- Interventions
- Drug: TT-01488 Tablets
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05683717
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TT-00973-MS tablets treatment
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05673538
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Phase 1 Study of TT-00920 in Healthy Subjects
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05355129
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05275504
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, United States
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Conditions
- Gallbladder CancerProstate CancerThyroid CancerAdvanced Solid TumorCholangiocarcinomaTriple Negative Breast CancerGastric CancerBiliary Tract CancerHER2-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05253053
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05043792
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
- Conditions
- CholangiocarcinomaFGFR2 FusionFGFR2 Gene MutationFGFR1 AlterationFGFR3 Alteration
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04919642
- Locations
- 🇺🇸
Providence Cancer Center, Anchorage, Alaska, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California, Los Angeles, School of Medicine, Santa Monica, California, United States